A recent study has found a groundbreaking way to restore immunity in babies born without an immune system. Using a disabled form of HIV, researchers were able to correct the stem cells of babies with severe combined immunodeficiency (SCID), a rare genetic condition that severely impacts white blood cells. This condition, commonly known as ‘bubble boy disease’, can be fatal without treatment. The standard treatment for SCID is a bone marrow transplant, but gene therapy is now offering a new option for babies like Cora Oakley, who was diagnosed with SCID as an infant.
In the study, researchers followed 62 babies with ADA-SCID who received gene therapy and found that after almost eight years, every single one was still alive. In 95% of these cases, the therapy fully restored the babies’ immune systems, offering hope for a better quality of life. This new approach is a significant advancement in the treatment of SCID, with gene therapies currently being tested for four of SCID’s 20 subtypes.
The therapy involves correcting faulty genes by introducing a healthy copy using a disabled form of HIV as a carrier. This method allows for the production of healthy immune cells in babies with SCID. Unlike traditional bone marrow transplants, this treatment involves minimal chemotherapy and carries lower risks of rejection or requiring immunosuppression.
Despite the positive results, living with SCID can still be challenging for families. The need to protect babies from infections while their immune system rebuilds creates a constant state of anxiety for parents. While gene therapy shows promise, doctors emphasize that it’s still a relatively new approach compared to bone marrow transplants.
One major challenge is the high cost associated with gene therapy, which can run into millions of dollars per patient. Access to this groundbreaking treatment remains limited, with most options available only through clinical trials. The long-term sustainability of gene therapy and its potential risks are areas that require further research.
For families like Cora Oakley’s, gene therapy has provided a new lease on life. Cora, now 8 years old, is enjoying a normal childhood, free from the constraints of SCID. Her story is a testament to the power of medical advancements and the hope they bring to families facing rare genetic conditions affecting immunity.
Deixe um comentário